SILODOSIN

Search structure


Trade Names:	RAPAFLO SILODOSIN
Synonyms:	KAD-3213 KMD-3213 Kso-0400 Rapaflo Rapilif Silodal Silodosin Silodyx Urief Urorec
Status:	Approved (2008)
Entry Type:	Small molecule
Molecule Category:	UNKNOWN
ATC:	G04CA04
UNII:	CUZ39LUY82

Structure


InChI Key	PNCPYILNMDWPEY-QGZVFWFLSA-N
Smile	C[C@H](Cc1cc2c(c(C(N)=O)c1)N(CCCO)CC2)NCCOc1ccccc1OCC(F)(F)F
InChI	InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C25H32F3N3O4
Molecular Weight	495.54
AlogP	3.07
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	13.0
Polar Surface Area	97.05
Molecular species	BASE
Aromatic Rings	2.0
Heavy Atoms	35.0

Pharmacology

Action	Mechanism of Action	Reference
ANTAGONIST	Alpha-1a adrenergic receptor antagonist	DailyMed

	Primary Target
α_1A-adrenoceptor

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Ion channel Voltage-gated ion channel Potassium channels Voltage-gated potassium channel	-	7943-25119	-	-	-
Ion channel Voltage-gated ion channel Voltage-gated sodium channel	-	63096	-	-	-
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Monoamine receptor Adrenergic receptor	-	116-541	-	0-0	100

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Prostatic Hyperplasia	4	D011470	ClinicalTrials
Prostatic Neoplasms, Castration-Resistant	3	D064129	ClinicalTrials
Kidney Calculi	3	D007669	ClinicalTrials
Prostatitis	2	D011472	ClinicalTrials

Related Entries

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Side Effects from Label

Side Effects (PT)

Side effects	Relative Frequency (%)	Labels
Reproductive system and breast disorders Retrograde ejaculation	28.1
Cardiac disorders Dizziness	3.22
Reproductive system and breast disorders Retrograde ejaculation	2.8
Gastrointestinal disorders Diarrhoea	2.58
Nervous system disorders Orthostatic hypotension	2.58
Nervous system disorders Headache	2.36
Infections and infestations Nasopharyngitis	2.36
Infections and infestations Nasopharyngitis
Respiratory, thoracic and mediastinal disorders Nasal congestion	2.15
Nervous system disorders Orthostatic hypotension
Gastrointestinal disorders Diarrhoea
Cardiac disorders Dizziness
Nervous system disorders Headache
Reproductive system and breast disorders Retrograde ejaculation
Respiratory, thoracic and mediastinal disorders Nasal congestion

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Nervous system disorders	12.18
General disorders and administration site conditions	10.99
Injury, poisoning and procedural complications	7.65
Cardiac disorders	7.2
Vascular disorders	7.16
Respiratory, thoracic and mediastinal disorders	6.28
Gastrointestinal disorders	6.04
Reproductive system and breast disorders	5.48
Renal and urinary disorders	5.37
Skin and subcutaneous tissue disorders	5.27
Psychiatric disorders	4.28
Investigations	4.21
Musculoskeletal and connective tissue disorders	3.58
Immune system disorders	2.77
Eye disorders	2.7

Cross References

Resources	Reference
CAS NUMBER	160970-54-7
ChEBI	135929
ChEMBL	CHEMBL24778
DrugBank	DB06207
DrugCentral	4151
EPA CompTox	DTXSID40167045
FDA SRS	CUZ39LUY82
Guide to Pharmacology	493
KEGG	D01965
PubChem	5312125
SureChEMBL	SCHEMBL136973
ZINC	ZINC000003806063

CONTENTS